Shares of Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) fell 4% on Tuesday . The company traded as low as $19.58 and last traded at $19.58. 708 shares traded hands during trading, a decline of 99% from the average session volume of 81,598 shares. The stock had previously closed at $20.40.
Analysts Set New Price Targets
Separately, JPMorgan Chase & Co. assumed coverage on Ascentage Pharma Group International in a research report on Thursday, March 27th. They set an “overweight” rating for the company.
Check Out Our Latest Stock Analysis on Ascentage Pharma Group International
Ascentage Pharma Group International Stock Down 6.8 %
Ascentage Pharma Group International Company Profile
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
See Also
- Five stocks we like better than Ascentage Pharma Group International
- How to Invest in the FAANG Stocks
- Joby Aviation: Operational Momentum vs. Market Sentiment
- What Are Dividends? Buy the Best Dividend Stocks
- Broadcom’s Big Outperformance Shows Strength Amid Tariff Decline
- The Significance of Brokerage Rankings in Stock Selection
- Carvana: Can Turnaround Strength Outdrive Market Headwinds?
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
